Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $1 | $1 | $1 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.7% | 53.7% | 20.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |